Showing 1-10 of 328 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| A Novel Ultra-Rapid Insulin | Wayne State University | Zhiqiang Cao | Improving Lives | 01-November-2025 to 31-October-2026 | $299.994,92 |
| ALIGN-T1D Start-Up Secretariat | Clinton Health Access Initiative (CHAI) | Nine Steensma | Mission | 01-October-2025 to 31-March-2027 | $2.348.396,21 |
| Thermally responsive minimally invasive proangiogenic placeholder for cell transplantation for Type 1 Diabetes | University of Washington | Patrick Stayton | Cures | 01-November-2025 to 31-October-2028 | $894.965,96 |
| Clinical Translation of T-1123, an Ultra-rapid, Concentrated, Temperature stable Novel Insulin Analog | Invictus Therapeutics, LLC | Robyn Day | Improving Lives | 15-October-2025 to 31-May-2027 | $1.437.112,00 |
| A Cure for Type 1 Diabetes | University of Massachusetts Medical School | David Harlan | Cures | 01-October-2025 to 30-September-2029 | $16.000.000,00 |
| Evaluating the Impact of High-Risk HLA-DR Serotypes on the Cellular Neighborhood of the Pancreatic Islets: Towards Early Identification of T1D Disease Risk and Prevention | Missouri University of Science and Technology | Gina Yosten | Cures | 01-October-2025 to 30-September-2028 | $740.097,60 |
| Combination therapy with STX4 activating small molecules or small activating RNA together with harmine to stimulate beta-cell regeneration and enhance functional beta-cell mass | Beckman Research Institute of the City of Hope | Debbie Thurmond | Cures | 01-October-2025 to 30-September-2028 | $1.050.000,00 |
| Dual Beta-cell Regenerative and Immunomodulatory Endogenous Agonist as a Replacement Therapy for Type 1 Diabetes | Rector & Visitors of the University of Virginia | Gordon Laurie | Cures | 01-October-2025 to 30-September-2027 | $300.000,00 |
| Understanding common tissue tolerance mechanisms in autoimmunity | Massachusetts General Hospital | Gary Reynolds | Cures | 01-September-2025 to 31-August-2026 | $150.000,00 |
| A glucose-responsive cannula of insulin delivery | Cornell University | Bo Wang | Improving Lives | 01-March-2023 to 28-February-2025 | $198.731,24 |